4.7 Article

Monte Carlo Simulations Based on Phase 1 Studies Predict Target Attainment of Ceftobiprole in Nosocomial Pneumonia Patients: a Validation Study

期刊

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
卷 57, 期 5, 页码 2047-2053

出版社

AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.02292-12

关键词

-

资金

  1. Basilea Pharmaceutica Ltd.
  2. EU project Saturn [Health-F3-2009-241796]

向作者/读者索取更多资源

Monte Carlo simulation (MCS) of antimicrobial dosage regimens during drug development to derive predicted target attainment values is frequently used to choose the optimal dose for the treatment of patients in phase 2 and 3 studies. A criticism is that pharmacokinetic (PK) parameter estimates and variability in healthy volunteers are smaller than those in patients. In this study, the initial estimates of exposure from MCS were compared with actual exposure data in patients treated with ceftobiprole in a phase 3 nosocomial-pneumonia (NP) study (NTC00210964). Results of MCS using population PK data from ceftobiprole derived from 12 healthy volunteers were used (J. W. Mouton, A. Schmitt-Hoffmann, S. Shapiro, N. Nashed, N. C. Punt, Antimicrob. Agents Chemother. 48: 1713-1718, 2004). Actual individual exposures in patients were derived after building a population pharmacokinetic model and were used to calculate the individual exposure to ceftobiprole (the percentage of time the unbound concentration exceeds the MIC [percent fT > MIC]) for a range of MIC values. For the ranges of percent fT > MIC used to determine the dosage schedule in the phase 3 NP study, the MCS using data from a single phase 1 study in healthy volunteers accurately predicted the actual clinical exposure to ceftobiprole. The difference at 50% fT > MIC at an MIC of 4 mg/liter was 3.5% for PK-sampled patients. For higher values of percent fT > MIC and MICs, the MCS slightly underestimated the target attainment, probably due to extreme values in the PK profile distribution used in the simulations. The probability of target attainment based on MCS in healthy volunteers adequately predicted the actual exposures in a patient population, including severely ill patients.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Medical Laboratory Technology

Health Care Costs of Target Attainment for Beta-Lactam Antibiotics in Critically Ill Patients: A Retrospective Analysis of the EXPAT Study

Tim M. J. Ewoldt, Alan Abdulla, Nicole G. M. Hunfeld, Anouk E. Muller, Diederik Gommers, Suzanne Polinder, Birgit C. P. Koch, Henrik Endeman

Summary: This study found that target attainment for beta-lactam antibiotics in ICU patients shows a trend towards higher total costs, which can be attributed to the costs of long ICU stays and renal replacement therapy.

THERAPEUTIC DRUG MONITORING (2022)

Article Infectious Diseases

Nitrofurantoin 100 mg versus 50 mg prophylaxis for urinary tract infections, a cohort study

Thijs ten Doesschate, Kelly Hendriks, Cornelis Henri van Werkhoven, Evelien C. van der Hout, Tamara N. Platteel, Irene A. M. Groenewegen, Anouk E. Muller, Andy I. M. Hoepelman, Marc J. M. Bonten, Suzanne E. Geerlings

Summary: This study compares the effectiveness and safety of daily prophylaxis with 50 mg or 100 mg nitrofurantoin for recurrent urinary tract infection. The results show that there is no significant difference in the risk of UTI or pyelonephritis between the two dosages, but there is a higher risk of cough, dyspnea, and nausea with the 100 mg dosage.

CLINICAL MICROBIOLOGY AND INFECTION (2022)

Review Medical Laboratory Technology

Therapeutic Drug Monitoring of Antibiotics in Critically Ill Patients: Current Practice and Future Perspectives With a Focus on Clinical Outcome

Birgit C. P. Koch, Anouk E. Muller, Nicole G. M. Hunfeld, Brenda C. M. de Winter, Tim M. J. Ewoldt, Alan Abdulla, Henrik Endeman

Summary: Early initiation of antibiotics and correct dosing are essential for improving infections in critically ill patients. However, the altered pharmacokinetic parameters and less susceptible microorganisms pose challenges to ensuring optimal antibiotic exposure. Therapeutic drug monitoring (TDM) is a commonly used strategy to support individualized dosing of antibiotics. This review recommends implementing TDM for glycopeptides and aminoglycosides, and suggests performing TDM in specific patient cases for antibiotics such as beta-lactams, fluoroquinolones, and linezolid. Future possibilities for improving TDM include model-informed precision dosing and the use of rapid bioanalytical techniques or biosensors for real-time monitoring of drug concentrations.

THERAPEUTIC DRUG MONITORING (2022)

Review Medical Laboratory Technology

Barriers and Facilitators in the Clinical Implementation of Beta-Lactam Therapeutic Drug Monitoring in Critically Ill Patients: A Critical Review

Alan Abdulla, Puck van den Broek, Tim M. J. Ewoldt, Anouk E. Muller, Henrik Endeman, Birgit C. P. Koch

Summary: This study provides an overview of the current practices of beta-lactam therapeutic drug monitoring (TDM) and identifies barriers and facilitators in its clinical implementation. The main barriers include insufficient knowledge and unavailability of assays, while doubts about cost-effectiveness and clinical effectiveness hinder its broad implementation. Collaboration between physicians and clinical pharmacists and microbiologists can improve physicians' willingness to use beta-lactam TDM.

THERAPEUTIC DRUG MONITORING (2022)

Article Pharmacology & Pharmacy

Parametric and Nonparametric Population Pharmacokinetic Models to Assess Probability of Target Attainment of Imipenem Concentrations in Critically Ill Patients

Femke de Velde, Brenda C. M. de Winter, Michael N. Neely, Jan Strojil, Walter M. Yamada, Stephan Harbarth, Angela Huttner, Teun van Gelder, Birgit C. P. Koch, Anouk E. Muller

Summary: Population pharmacokinetic modeling and simulation are used in antibiotic dosing optimization, with parametric and nonparametric models showing differences in predictive performance and target attainment probability calculations. The study found that while both models had satisfactory predictive performance for high eGFR values, they were insufficient for lower eGFR values, with the nonparametric model resulting in lower MICs due to higher estimated between-subject variability.

PHARMACEUTICS (2021)

Review Pharmacology & Pharmacy

Pharmacokinetics of Clavulanic Acid in the Pediatric Population: A Systematic Literature Review

Fleur M. Keij, Gerdien A. Tramper-Stranders, Birgit C. P. Koch, Irwin K. M. Reiss, Anouk E. Muller, Rene F. Kornelisse, Karel Allegaert

Summary: The pharmacokinetics of clavulanic acid in pediatric patients is highly variable, similar to reports in adults, but more pronounced. There is a lack of knowledge regarding the specific population-specific explanation for this variability. Model-based pharmacokinetic studies addressing maturational and disease-specific changes in the pediatric population as well as additional pharmacodynamic studies are needed to define a clear target.

CLINICAL PHARMACOKINETICS (2022)

Article Pharmacology & Pharmacy

Pharmacokinetic Modeling of Hydrocortisone by Including Protein Binding to Corticosteroid-Binding Globulin

Eric Rozenveld, Nieko Punt, Martijn van Faassen, Andre P. van Beek, Daan J. Touw

Summary: This study analyzed the pharmacokinetics of hydrocortisone in patients with adrenal insufficiency, incorporating protein binding states into the PK model. The new model showed improved predictive ability for free cortisol concentrations and better correlations between total and free hydrocortisone AUC(24) compared to the old model.

PHARMACEUTICS (2022)

Article Infectious Diseases

Pharmacodynamics of Flucloxacillin in a Neutropenic Murine Thigh Infection Model: A Piece of the Puzzle towards Evidence-Based Dosing

Eveline E. Roelofsen, Brenda C. M. de Winter, Heleen van der Spek, Susan Snijders, Birgit C. P. Koch, Sanne van den Berg, Anouk E. Muller

Summary: For decades, flucloxacillin has been used to treat methicillin-susceptible Staphylococcus aureus (MSSA). This study aimed to determine the pharmacokinetic/pharmacodynamic (PK/PD) index and the required PD-index value for efficacy. The results provide insights for optimizing dosing regimens in humans.

ANTIBIOTICS-BASEL (2022)

Article Microbiology

Pharmacodynamics of Temocillin in Neutropenic Murine Infection Models

Anouk E. E. Muller, Merel Raaphorst, Aart van der Meijden, Brenda C. M. de Winter, Joseph Meletiadis, Sanne van den Berg

Summary: This study investigated the pharmacokinetics of temocillin in plasma and epithelial lining fluid in infected neutropenic mice, and determined the exposure-response relationships for Escherichia coli and Klebsiella pneumoniae. The results showed that temocillin achieved a static effect in the lung infection model with a lower median %fT>MIC compared to the thigh infection model, indicating its potential use in patients with pneumonia.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2023)

Article Infectious Diseases

Pharmacokinetic and pharmacodynamic properties of polymyxin B in Escherichia coli and Klebsiella pneumoniae murine infection models

Aart van der Meijden, Vincent Aranzana-Climent, Heleen van der Spek, Brenda C. M. de Winter, William Couet, Joseph Meletiadis, Anouk E. Muller, Sanne van den Berg

Summary: In this study, the pharmacokinetics and pharmacodynamics of polymyxin B were determined in neutropenic infected mice. The fAUC/MIC index was found to best describe the drug’s effectiveness. However, the standard dosing regimen did not achieve the PK/PD targets for the majority of clinical isolates, suggesting that polymyxin B may be ineffective as monotherapy for serious infections.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2023)

Article Infectious Diseases

Voriconazole exposure is influenced by inflammation: A population pharmacokinetic model

D. Abraham Van den Born, Anne-Grete Martson, Anette Veringa, Nieko C. Punt, Tjip S. Van der Werf, Jan-Willem C. Alffenaar, Marieke G. G. Sturkenboom, Daan J. Touw

Summary: This study investigated the effect of inflammation on the metabolism of voriconazole and found that C-reactive protein (CRP) was the only significant covariate. The final pharmacokinetic model, which included CRP as a covariate, can be applied in clinical care.

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2023)

Article Infectious Diseases

Meropenem Model-Informed Precision Dosing in the Treatment of Critically Ill Patients: Can We Use It?

Letao Li, Sebastiaan D. T. Sassen, Tim M. J. Ewoldt, Alan Abdulla, Nicole G. M. Hunfeld, Anouk E. Muller, Brenda C. M. de Winter, Henrik Endeman, Birgit C. P. Koch

Summary: The suitability of published meropenem pharmacokinetic models for clinical practice was evaluated using real-world ICU data, and two models were found to perform well when using two to three plasma concentrations for therapeutic drug monitoring, while the other models performed poorly.

ANTIBIOTICS-BASEL (2023)

Article Microbiology

In Vitro-In Vivo Correlation of Posaconazole-Amphotericin B Combination against Candida albicans: In Vitro Interacting Concentrations Are Associated with In Vivo Free Drug Levels

Joseph Meletiadis, Maria-Ioanna Beredaki, Antigoni Elefanti, Spyros Pournaras, Anouk Muller

Summary: In order to evaluate the efficacy of combination therapy, it is necessary to study the correlation between in vitro and in vivo testing. This study attempted to correlate the in vitro chequerboard testing of posaconazole and amphotericin B with the in vivo outcome of combination therapy. The results showed consistency between the in vitro and in vivo testing.

JOURNAL OF FUNGI (2023)

Article Pharmacology & Pharmacy

Tutorial on model selection and validation of model input into precision dosing software for model-informed precision dosing

Zachary L. Taylor, Ethan A. Poweleit, Kelli Paice, Katherine M. Somers, Kathryn Pavia, Alexander A. Vinks, Nieko Punt, Tomoyuki Mizuno, Sonya Tang Girdwood

Summary: There is increasing interest in using model-informed precision dosing to provide personalized medicine at the bedside. This tutorial provides a comprehensive approach to evaluating, selecting, and validating a model for implementation into a precision dosing program.

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2023)

Article Critical Care Medicine

Target attainment and population pharmacokinetics of flucloxacillin in critically ill patients: a multicenter study

Sjoerd D. D. Meenks, Nieko Punt, Jos L. M. L. le Noble, Norbert A. A. Foudraine, Kees Neef, Paddy K. C. Janssen

Summary: This study assessed the population pharmacokinetics and target attainment of flucloxacillin in critically ill patients. The results showed that standard daily doses may substantially increase the risk of underdosing in critically ill patients. Further validation of these model predictions is needed.

CRITICAL CARE (2023)

暂无数据